LEO Pharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

LEO Pharma A/S (LEO Pharma), a subsidiary of LEO Foundation is a research-based pharmaceutical company. It discovers, develops, manufactures and commercializes pharmaceuticals in therapeutic areas dermatology and thrombosis. The company focuses on the treatment of diseases such as psoriasis, eczema, skin infections, actinic keratosis and non-melanoma skin cancer, besides thrombosis. It also manufactures and markets products for the treatment of diseases in the areas of cardiovascular, bacterial infections, coagulation, osteoporosis and renal care. LEO Pharma markets its products worldwide and has presence in countries across Europe, the Middle East, Africa, Asia, North America, Central America, South America and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.

LEO Pharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 13
Partnerships 14
Leo Pharma Enters into Licensing Agreement with Klox Technologies 14
HitGen Enters into Research Agreement with LEO Pharma 15
LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 16
Klox Technologies and LEO Pharma to Form Joint Venture 17
MorphoSys Enters into Agreement with LEO Pharma 18
LEO Pharma Enters into Agreement with Washington University School of Medicine 19
Leo Pharma Enters into Distribution Agreement with NeoPharm 20
arGEN-X Enters into Co-Development Agreement with Leo Pharma 21
Fidelta Enters into Drug Discovery Agreement with LEO Pharma 22
Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 23
LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 24
LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 25
LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 26
Licensing Agreements 27
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 27
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 28
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Brodalumab 29
Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 30
Equity Offering 31
LEO Pharma Invests in Novopyxis 31
Asset Transactions 32
Karo Pharma to Acquire Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 32
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 34
LEO Pharma A/S - Key Competitors 35
LEO Pharma A/S - Key Employees 36
LEO Pharma A/S - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Financial Announcements 39
Mar 02, 2018: A record year for LEO Pharma 39
Apr 03, 2017: LEO Pharma 2016 result surpassed expectations 41
Corporate Communications 43
Mar 20, 2018: LEO Pharma Appoints Rhonda Duffy To Lead Global Product Supply 43
Jun 23, 2017: LEO Pharma Appoints Chris Posner to Lead US Business 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables

List of Tables
LEO Pharma A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LEO Pharma A/S, Deals By Therapy Area, 2012 to YTD 2018 9
LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 13
Leo Pharma Enters into Licensing Agreement with Klox Technologies 14
HitGen Enters into Research Agreement with LEO Pharma 15
LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 16
Klox Technologies and LEO Pharma to Form Joint Venture 17
MorphoSys Enters into Agreement with LEO Pharma 18
LEO Pharma Enters into Agreement with Washington University School of Medicine 19
Leo Pharma Enters into Distribution Agreement with NeoPharm 20
arGEN-X Enters into Co-Development Agreement with Leo Pharma 21
Fidelta Enters into Drug Discovery Agreement with LEO Pharma 22
Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 23
LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 24
LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 25
LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 26
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 27
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 28
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Brodalumab 29
Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 30
LEO Pharma Invests in Novopyxis 31
Karo Pharma to Acquire Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 32
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 34
LEO Pharma A/S, Key Competitors 35
LEO Pharma A/S, Key Employees 36
LEO Pharma A/S, Subsidiaries 37

List Of Figures

List of Figures
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10

Valeo Pharma Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Valeo Pharma Inc (Valeo Pharma), a subsidiary of Manitex Capital Inc, is a pharmaceutical company that offers healthcare solutions and specialty products. The company provides dermatology products such as drops,

USD 250 View Report

5 Nucleotidase (Ecto 5 Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2018

5 Nucleotidase (Ecto 5 Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 20185 Nucleotidase (Ecto 5 Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target

USD 3500 View Report

Fertin Pharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fertin Pharma A/S (Fertin Pharma) is a pharmaceutical company that develops and manufactures medicated chewing gum. The company offers pharmaceutical chewing gum products for therapeutic areas such as allergy, cough

USD 250 View Report

Valeo Pharma Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Valeo Pharma Inc (Valeo Pharma), a subsidiary of Manitex Capital Inc, is a pharmaceutical company that offers healthcare solutions and specialty products. The company provides dermatology products such as drops,

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available